A Multicenter Cohort Study for XELOX (Capecitabine, Leucovorin plus Oxaliplatin) Therapy as First-Line Treatment in Elderly Patients with Unresectable Colorectal Cancer

Tetsu Yamamoto^1*, Ryoji Hyakudomi¹, Shinichi Sugimoto², Atsuo Tokuka², Yoshitoshi Sato³, Satoshi Nagai⁴, Hikota Hayashi¹, Masahikoo Igarashi⁵, Kenji Takubo³, Yoshitsugu Tajima¹

¹Department of Digestive and General Surgery, Faculty of Medicine, Shimane University, Izumo, Japan.
²Department of Surgery, Shimane Prefectural Central Hospital, Izumo, Japan.
³Department of Gastroenterological Surgery, Matsue Red Cross Hospital, Matsue, Japan.
⁴Department of Surgery, National Hospital Organization Hamada Medical Center, Hamada, Japan.
⁵Department of Surgery, Masuda Medical Association Hospital, Masuda, Japan.

DOI: 10.4236/jct.2015.62017                

Abstract

Oxaliplatin-based chemotherapy with bevacizumab is now widely used for colorectal cancer patients. This study evaluated the efficacy and tolerability of XELOX (capecitabine + oxaliplatin + leucovorin combined) therapy with or without bevacizumab in elderly patients. One hundred and seven patients, consisting of 52 elderly (>70 years of age) and 55 non-elderly, with unresectable colorectal cancer were enrolled in this multicenter cooperative group study using a database between October 2009 and March 2012. We evaluated the outcomes in terms of the median time to treat failure (TTF), overall response rate (ORR), disease control rate (DCR) and tolerability in both age groups. The median TTF for the XELOX + bevacizumab regimen was 7.1 months in the non-elderly group and 8.1 months in the elderly group (p = 0.838). There was no significant difference in TTF between the two groups. The ORR and DCR in the non-elderly group were 30.8% and 73.1%, respectively. In the elderly group, the ORR was 40.0% and the overall DCR was 90.0%. No severe or uncontrollable adverse events were observed in the two groups. These data indicated that the XELOX chemotherapy with or without bevacizumab has an equivalent efficacy in both groups, without increasing the adverse events even in the elderly population.

Keywords

Colorectal Cancer, Oxaliplatin, Capecitabine, Bevacizumab, Elderly Patients

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Golfinopoulos, V., Salanti, G., Pavlidis, N. and Ioannidis, J.P. (2007) Survival and Disease-Progression Benefits with Treatment Regimens for Advanced Colorectal Cancer: A Meta-Analysis. The Lancet Oncology, 8, 898-911. http://dx.doi.org/10.1016/S1470-2045(07)70281-4
[2]	Rothenberg, M.L., Cox, J.V., Butts, C., Navarro, M., Goel, R., Gollins, S., Siu, L.L., Laguerre, S. and Cunningham, D. (2008) Capecitabine plus Oxaliplatin (XELOX) versus 5-Fluorouracil/Folinic Acid plus Oxaliplatin (FOLFOX-4) as Second-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Noninferiority Study. Annals of Oncology, 19, 1720-1726. http://dx.doi.org/10.1093/annonc/mdn370
[3]	Saltz, L.B., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.S., Rivera, F., Couture, F., Sirzen, F. and Cassidy, J. (2008) Bevacizumab in Combination with Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology, 26, 2013-2019. http://dx.doi.org/10.1200/JCO.2007.14.9930
[4]	Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., Meropol, N.J., Novotny, W.F., Lieberman, G., Griffing, S. and Bergsland, E. (2003) Phase II, Randomized Trial Comparing Bevacizumab plus Fluorouracil (FU)/Leucovorin (LV) with FU/LV Alone in Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology, 21, 60-65. http://dx.doi.org/10.1200/JCO.2003.10.066
[5]	Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R. and Kabbinavar, F. (2004) Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. The New England Journal of Medicine, 350, 2335-2342. http://dx.doi.org/10.1056/NEJMoa032691
[6]	Argyriou, A.A., Polychronopoulos, P., Iconomou, G., Chroni, E. and Kalofonos, H.P. (2008) A Review on Oxaliplatin-Induced Peripheral Nerve Damage. Cancer Treatment Reviews, 34, 368-377. http://dx.doi.org/10.1016/j.ctrv.2008.01.003
[7]	Scappaticci, F.A., Skillings, J.R., Holden, S.N., Gerber, H.P., Miller, K., Kabbinavar, F., Bergsland, E., Ngai, J., Holmgren, E., Wang, J. and Hurwitz, H. (2007) Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab. Journal of the National Cancer Institute, 99, 1232-1239. http://dx.doi.org/10.1093/jnci/djm086
[8]	Kohne, C.H., Grothey, A., Bokemeyer, C., Bontke, N. and Aapro, M. (2001) Chemotherapy in Elderly Patients with Colorectal Cancer. Annals of Oncology, 12, 435-442. http://dx.doi.org/10.1023/A:1011170808734
[9]	Folprecht, G., Cunningham, D., Ross, P., Glimelius, B., Di Costanzo, F., Wils, J., Scheithauer, W., Rougier, P., Aranda, E., Hecker, H. and Kohne, C.H. (2004) Efficacy of 5-Fluorouracil-Based Chemotherapy in Elderly Patients with Metastatic Colorectal Cancer: A Pooled Analysis of Clinical Trials. Annals of Oncology, 15, 1330-1338. http://dx.doi.org/10.1093/annonc/mdh344
[10]	Yamamoto, T., Katano, K., Sugimoto, S., Kanazawa, A., Hira, E., Takeda, H., Sato, Y., Yamashiro, Y., Tajima, Y. and Ikeguchi, M. (2014) Multicenter Analysis of mFOLFOX6 with Oxaliplatin Stop-and-Go Strategy Using Oral Uracil-Tegafur with Leucovorin for Unresectable Colorectal Cancer in Elderly Patients. Journal of Cancer Therapy, 5, 146-153. http://dx.doi.org/10.4236/jct.2014.52018
[11]	Hutchins, L.F., Unger, J.M., Crowley, J.J., Coltman Jr., C.A. and Albain, K.S. (1999) Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials. New England Journal of Medicine, 341, 2061-2067. http://dx.doi.org/10.1056/NEJM199912303412706
[12]	Venderbosch, S., Doornebal, J., Teerenstra, S., Lemmens, W., Punt, C.J. and Koopman, M. (2012) Outcome of First Line Systemic Treatment in Elderly Compared to Younger Patients with Metastatic Colorectal Cancer: A Retrospective Analysis of the CAIRO and CAIRO2 Studies of the Dutch Colorectal Cancer Group (DCCG). Acta Oncologica, 51, 831-839. http://dx.doi.org/10.3109/0284186X.2012.699193
[13]	Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A.T., Christian, M.C. and Gwyther, S.G. (2000) New Guidelines to Evaluate the Response to Treatment in Solid Tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute, 92, 205-216. http://dx.doi.org/10.1093/jnci/92.3.205
[14]	Chen, A.P., Setser, A., Anadkat, M.J., Cotliar, J., Olsen, E.A., Garden, B.C. and Lacouture, M.E. (2012) Grading Dermatologic Adverse Events of Cancer Treatments: The Common Terminology Criteria for Adverse Events Version 4.0. Journal of the American Academy of Dermatology, 67, 1025-1039. http://dx.doi.org/10.1016/j.jaad.2012.02.010
[15]	Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D. and Verweij, J. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline. European Journal of Cancer, 45, 228-247. http://dx.doi.org/10.1016/j.ejca.2008.10.026
[16]	Kabbinavar, F.F., Hurwitz, H.I., Yi, J., Sarkar, S. and Rosen, O. (2009) Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients from Two Randomized Clinical Trials. Journal of Clinical Oncology, 27, 199-205. http://dx.doi.org/10.1200/JCO.2008.17.7931
[17]	Cassidy, J., Saltz, L.B., Giantonio, B.J., Kabbinavar, F.F., Hurwitz, H.I. and Rohr, U.P. (2010) Effect of Bevacizumab in Older Patients with Metastatic Colorectal Cancer: Pooled Analysis of Four Randomized Studies. Journal of Cancer Research and Clinical Oncology, 136, 737-743. http://dx.doi.org/10.1007/s00432-009-0712-3
[18]	Kozloff, M.F., Berlin, J., Flynn, P.J., Kabbinavar, F., Ashby, M., Dong, W., Sing, A.P. and Grothey, A. (2010) Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study. Oncology, 78, 329-339. http://dx.doi.org/10.1159/000320222
[19]	Greenblatt, D.J., Sellers, E.M. and Shader, R.I. (1982) Drug Disposition in Old Age. New England Journal of Medicine, 306, 1081-1088. http://dx.doi.org/10.1056/NEJM198205063061804
[20]	Montamat, S.C., Cusack, B.J. and Vestal, R.E. (1989) Management of Drug Therapy in the Elderly. New England Journal of Medicine, 321, 303-309. http://dx.doi.org/10.1056/NEJM198908033210507
[21]	Silverstein, M.D., Heit, J.A., Mohr, D.N., Petterson, T.M., O’Fallon, W.M. and Melton, L.J. (1998) Trends in the Incidence of Deep Vein Thrombosis and Pulmonary Embolism: A 25-Year Population-Based Study. JAMA Internal Medicine, 158, 585-593. http://dx.doi.org/10.1001/archinte.158.6.585
[22]	Goldberg, R.M., Tabah-Fisch, I., Bleiberg, H., de Gramont, A., Tournigand, C., Andre, T., Rothenberg, M.L., Green, E. and Sargent, D.J. (2006) Pooled Analysis of Safety and Efficacy of Oxaliplatin plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients with Colorectal Cancer. Journal of Clinical Oncology, 24, 4085-4091. http://dx.doi.org/10.1200/JCO.2006.06.9039
[23]	Tournigand, C., Cervantes, A., Figer, A., Lledo, G., Flesch, M., Buyse, M., Mineur, L., Carola, E., Etienne, P.L., Rivera, F., Chirivella, I., Perez-Staub, N., Louvet, C., André, T., Tabah-Fisch, I. and de Gramont, A. (2006) OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 with Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study. Journal of Clinical Oncology, 24, 394-400. http://dx.doi.org/10.1200/JCO.2005.03.0106